Kodiak Sciences (NASDAQ: KOD) director Baker Bros. buys $24.34 million of stock
by Tristan Rich · The Markets DailyWhat happened
Baker Bros. Advisors LP, a Kodiak Sciences Inc. (NASDAQ: KOD) director and 10% owner, bought 247,090 shares for about $24.34 million. Every purchase was at $98.51 a share on Nov. 4 or Nov. 5, according to the Form 4 signed Nov. 6.
The shares went to two Baker funds that hold the stock directly. On Nov. 4, 667, L.P. bought 8,742 shares and Baker Brothers Life Sciences, L.P. bought 151,916. On Nov. 5 they bought 4,703 and 81,729.
After the purchases, the filing lists 20,424,859 shares for Life Sciences and 1,683,172 for 667. The adviser has complete discretion over the investment and voting power of the shares both funds hold.
Felix J. Baker, a managing member of the adviser's general partner, is a Kodiak director. Because of that board representation, the filing treats the other reporting persons as directors by deputization.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares bought | 247,090 shares | SEC Form 4 | |
| Price per share | $98.51 | SEC Form 4 | |
| Total purchase value | $24.34 million | SEC Form 4 | |
| Shares held after purchases (larger reported line) | 20,424,859 shares | SEC Form 4 |
Read more: Kodiak Sciences (KOD) company research
Why it matters
A holder with a board seat and control of the funds' votes added to its Kodiak position at one price over two days. OptimistFi has argued that Kodiak's value depends on whether its drug platform can produce differentiated, financeable medicines before cash burn or competition absorbs the upside. It reads continued buying by a board-linked holder as a modest plus for the financeable half of that view.
Buying slowed on the second day. By OptimistFi's tally of the filing's lines, the funds bought 160,658 shares on Nov. 4 and 86,432 on Nov. 5.
The limits are plain. A purchase is a position decision, not a clinical, operating or financing result. The Bakers and the adviser also disclaim beneficial ownership of the funds' shares beyond their pecuniary interest.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Kodiak's next quarterly report is the next scheduled test. Its cash and spending figures bear on the cash-burn risk in OptimistFi's view: a slower burn would support the case, while faster spending would weaken it.
More from OptimistFi
- KOD stock: research and coverage of Kodiak Sciences
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
Sources
- SEC Form 4, Kodiak Sciences Inc. — Statement of changes in beneficial ownership filed by Baker Bros. Advisors LP and related reporting persons, signed Nov. 6, 2026.
Explore OptimistFi research on Kodiak Sciences Inc.: https://optimistfi.com/stocks/KOD
Browse Kodiak Sciences Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Kodiak Sciences Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.